Potential for Cannabis Consumption Spaces in BC省: Survey Results

Jan.11.2023
Potential for Cannabis Consumption Spaces in BC省: Survey Results
Canada's BC province released a report showing strong support for cannabis consumption facilities among users, but concerns about driving safety.

Special Statement:


This article is limited to conducting research on relevant industries and overseas markets. It does not recommend any products or provide commentary on any domestic policies.


The legitimacy of the product mentioned in the article is only applicable to its overseas location. Domestic readers are advised to take note and strictly adhere to relevant laws and regulations in China.


This article does not constitute any investment or financial advice.


This article is not suitable for minors to read.


The province of British Columbia in Canada has released a report titled "What We Heard", based on a 2022 investigation into the feasibility of marijuana consumption spaces.


A recent survey conducted through online and telephone channels has shown a strong support among marijuana consumers for marijuana-specific consumption venues, as well as concerns regarding the potential unsafe driving behavior caused by marijuana and alcohol consumption.


A total of 61% of phone survey respondents and 34% of online survey respondents expressed support for marijuana consumption facilities, according to a recent report. The report also suggests that variations in support may be linked to self-selection biases, as phone sampling is random while online surveys may be more targeted.


Compared to older Canadians, young people are also more likely to support cannabis consumption venues.


The feedback from this survey will help the provincial government to decide whether or not to allow cannabis consumption sites and how to implement them.


Although many people often think of smoking rooms or electronic cigarette lounges, the province's definition of cannabis consumption venues is broader, including specific cannabis consumption locations, consumption during festivals or other events, and even cannabis consumption in "non-cannabis primary locations".


As indoor smoking and vaping are prohibited by law, such venues are not being considered.


Earlier this year, the British Columbia government sought feedback from the public on what cannabis consumption spaces in the province could look like.


When considering how provincial marijuana policy will evolve, our top priority is health and safety," said Mike Farnworth, Minister of Public Safety and Solicitor General. "This report provides valuable insights into people's perceptions of marijuana in BC and will help guide our work to support a strong, diverse, and safe legal cannabis industry throughout the province.


The majority of survey respondents who reported using marijuana also expressed support for consumption venues, as did industry associations for marijuana retailers, producers, and those providing written opinions.


However, non-cannabis consumers and certain public health and safety organizations, as well as local governments, generally do not support such establishments.


A total of 730 individuals participated in the telephone survey, 15,362 completed the online survey, and 66 individuals, companies, and organizations provided written comments.


Exploring the feasibility of cannabis consumption venues is another way the province of British Columbia is working to support the success of the industry, said Brittany Anderson, Secretary of the Tourism Council. "With the recent introduction of farm sales licenses, understanding public attitudes towards cannabis-related hospitality and agritourism activities is the next practical step. The feedback in this report will play an important role in shaping provincial policy.


The ability to purchase and consume marijuana products, such as food and drink, in places where alcohol is also sold and consumed is a controversial topic. Among respondents who participated in a telephone survey, 42% support this model while 41% oppose it. In an online survey, 64% of respondents oppose this model, while only 32% support it.


Public health officials who oppose the co-location of cannabis consumption facilities with alcohol establishments cite concerns over double consumption and addiction as their main concerns. However, most cannabis industry affiliated organizations support co-existence with alcohol consumption venues. It is not yet clear what regulations the province will implement next with regards to cannabis consumption facilities.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22